Elimination of lymphatic filariasis as a public health problem in Niue under PacELF, 1999-2016.
Epidemiology
Lymphatic filariasis
Mass drug administration
Microfilaria
Niue
PacELF
Wuchereria bancrofti
Journal
Tropical medicine and health
ISSN: 1348-8945
Titre abrégé: Trop Med Health
Pays: Japan
ID NLM: 101215093
Informations de publication
Date de publication:
2019
2019
Historique:
received:
05
04
2018
accepted:
28
06
2018
entrez:
30
3
2019
pubmed:
30
3
2019
medline:
30
3
2019
Statut:
epublish
Résumé
Lymphatic filariasis (LF) is a mosquito-borne parasitic disease which is targeted for elimination as a public health problem worldwide. Niue is a small self-governing South Pacific island nation with approximately 1600 residents that was formerly LF endemic. Here, we review the progress made towards eliminating LF in Niue since 1999. This study has reviewed all the available literature relating to LF in Niue to assess surveillance efforts and the elimination of transmission. Reviewed documentation included both published and unpublished works including historical reports of LF, WHO PacELF records, and Niue Country Reports of the national LF elimination program. Niue conducted mapping of baseline LF endemicity by testing the total present and consenting population for LF antigen with immunochromatographic test (ICT) in 1999, when circulating filarial antigen prevalence was 3.1% (n = 1794). Five nationwide annual mass drug administration (MDA) rounds with albendazole (400 mg) and diethylcarbamazine citrate (DEC) were undertaken from 2000 to 2004, with coverage reported from distribution records ranging from 78 to 99% of the eligible population, which excluded pregnant women and children under 2 years of age. A further whole population survey using ICT in 2001 found 1.3% positive (n = 1630). In 2004, antigen prevalence had reduced to 0.2% (n = 1285). A similar post-MDA survey in 2009 indicated antigen prevalence to be 0.5% (n = 1378). Seven positive cases were re-tested and re-treated every six months until negative. After five rounds of MDA, Niue had reduced the LF antigen population prevalence in all ages from 3.1% to below 1% and maintained this prevalence for a further five years. Due to Niue's small population, surveillance was done by whole population surveys. Niue's results support the WHO recommended strategy that five to six rounds of annual MDA with effective population coverage can successfully interrupt the transmission of LF. Niue received official acknowledgement of the validation of elimination of LF as a public health problem by the WHO Director-General and WHO Western Pacific Regional Office (WPRO) Regional Director at the 67th session of the Regional Committee for the Western Pacific held in Manila in October 2016.
Sections du résumé
BACKGROUND
BACKGROUND
Lymphatic filariasis (LF) is a mosquito-borne parasitic disease which is targeted for elimination as a public health problem worldwide. Niue is a small self-governing South Pacific island nation with approximately 1600 residents that was formerly LF endemic. Here, we review the progress made towards eliminating LF in Niue since 1999.
METHODS
METHODS
This study has reviewed all the available literature relating to LF in Niue to assess surveillance efforts and the elimination of transmission. Reviewed documentation included both published and unpublished works including historical reports of LF, WHO PacELF records, and Niue Country Reports of the national LF elimination program.
FINDINGS
RESULTS
Niue conducted mapping of baseline LF endemicity by testing the total present and consenting population for LF antigen with immunochromatographic test (ICT) in 1999, when circulating filarial antigen prevalence was 3.1% (n = 1794). Five nationwide annual mass drug administration (MDA) rounds with albendazole (400 mg) and diethylcarbamazine citrate (DEC) were undertaken from 2000 to 2004, with coverage reported from distribution records ranging from 78 to 99% of the eligible population, which excluded pregnant women and children under 2 years of age. A further whole population survey using ICT in 2001 found 1.3% positive (n = 1630). In 2004, antigen prevalence had reduced to 0.2% (n = 1285). A similar post-MDA survey in 2009 indicated antigen prevalence to be 0.5% (n = 1378). Seven positive cases were re-tested and re-treated every six months until negative.
CONCLUSIONS
CONCLUSIONS
After five rounds of MDA, Niue had reduced the LF antigen population prevalence in all ages from 3.1% to below 1% and maintained this prevalence for a further five years. Due to Niue's small population, surveillance was done by whole population surveys. Niue's results support the WHO recommended strategy that five to six rounds of annual MDA with effective population coverage can successfully interrupt the transmission of LF. Niue received official acknowledgement of the validation of elimination of LF as a public health problem by the WHO Director-General and WHO Western Pacific Regional Office (WPRO) Regional Director at the 67th session of the Regional Committee for the Western Pacific held in Manila in October 2016.
Identifiants
pubmed: 30923457
doi: 10.1186/s41182-019-0141-1
pii: 141
pmc: PMC6420762
doi:
Types de publication
Journal Article
Langues
eng
Pagination
20Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Déclaration de conflit d'intérêts
The authors alone are responsible for the views expressed in this article and they do not necessarily represent the views, decisions or policies of the institutions with which they are affiliated.This was a secondary data analysis reviewing de-identified data.Manuscript does not contain data from any individually identifiable person.The authors declare that they have no competing interests.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Références
Lancet. 2000 Jul 8;356(9224):143
pubmed: 10963257
Int J Parasitol. 2002 Jul;32(8):947-60
pubmed: 12076624
Ann N Y Acad Sci. 2002 Dec;979:131-42; discussion 188-96
pubmed: 12543723
N Z Med J. 1957 Apr;56(312):136-7
pubmed: 13430971
BMC Infect Dis. 2009 Jun 12;9:92
pubmed: 19523192
Glob Health Action. 2014 Feb 13;7:23507
pubmed: 24560259
Parasit Vectors. 2014 Oct 11;7:466
pubmed: 25303991
PLoS Negl Trop Dis. 2014 Dec 11;8(12):e3328
pubmed: 25502758
Infect Dis Poverty. 2015 Jul 30;4:34
pubmed: 26229599
Trop Med Health. 2017 Jun 16;45:18
pubmed: 28630586
Trop Med Health. 2017 Nov 1;45:34
pubmed: 29118654